We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocol.
- Authors
Iehara, Tomoko; Yoneda, Akihiro; Kikuta, Atsushi; Muraji, Toshihiro; Tokiwa, Kazuaki; Takahashi, Hideto; Teramukai, Satoshi; Takimoto, Tetsuya; Yagyu, Shigeki; Hosoi, Hajime; Tajiri, Tatsuro; Japan Children’s Cancer Group Neuroblastoma Committee
- Abstract
<bold>Background: </bold>Few clinical trials have been reported for patients with intermediate-risk neuroblastoma because of the scarcity of the disease and the variety of clinical and biological characteristics. A multidisciplinary treatment that consists of multidrug chemotherapy and surgery is expected to lead to a good prognosis with few complications. Therefore, a clinical trial for patients with intermediate-risk tumors was designed to establish a standard treatment that reduces complications and achieves good outcomes.<bold>Methods: </bold>We planned a prospective phase 2, single-arm study of the efficacy of image-defined risk factors (IDRF)-based surgical decision and stepwise treatment intensification for patients with intermediate-risk neuroblastomas. For the localized tumor group, IDRF evaluations will be performed after each three-course chemotherapy, and surgery will be performed when appropriate. For patients with metastatic tumors, a total of five chemotherapy courses will be performed, and primary lesions will be removed when the IDRF becomes negative. The primary endpoint is 3-year progression-free survival rate, and the secondary endpoints include 3-year progression-free survival rates and overall survival rates of the localized group and the metastasis group and the incidence of adverse events. From international results, 75% is considered an appropriate 3-year progression-free survival rate. If this trial's expected 3-year progression-free survival rate of 85% is statistically greater than 75% in the lower limit of the 95.3% confidence interval, with an accuracy 10% (85 ± 10%), both groups require more than 65 patients.<bold>Discussion: </bold>This study is the first clinical trial on the efficacy of IDRF-based surgical decision and stepwise treatment intensification for patients with intermediate-risk neuroblastomas. We expect that this study will contribute to the establishment of a standard treatment for patients with intermediate-risk neuroblastoma.<bold>Trial Registration: </bold>UMIN000004700, jRCTs051180203; Registered on December 9, 2010.
- Subjects
PROGRESSION-free survival; CONFIDENCE intervals; CLINICAL trials; NEUROBLASTOMA; ADVERSE health care events; THERAPEUTICS
- Publication
BMC Pediatrics, 2020, Vol 20, Issue 1, p1
- ISSN
1471-2431
- Publication type
journal article
- DOI
10.1186/s12887-020-02061-5